Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 11/20 | 0.65 |
| ▸ | HSP90AB1 | P08238 | 3/20 | 0.54 |
| ▸ | ALOX5AP | P20292 | 5/20 | 0.39 |
| ▸ | FEN1 | P39748 | 5/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | F10 | P00742 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | IKBKB | O14920 | 1/20 | 0.35 |
| ▸ | CHUK | O15111 | 1/20 | 0.35 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.35 |
| ▸ | AURKAIP1 | Q9NWT8 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13144900 | 0.93 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1ALOX5APFEN1F10 | |
| SCHEMBL2510646 | 0.91 | HSP90AA1 (0.60) | HSP90AA1HSP90AB1ALOX5APFEN1F10 | |
| SCHEMBL2512437 | 0.90 | HSP90AA1 (0.63) | HSP90AA1HSP90AB1ALOX5APFEN1F10 | |
| SCHEMBL12199666 | 0.90 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1ALOX5APFEN1F10 | |
| SCHEMBL2512175 | 0.88 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1ALOX5APFEN1F10 | |
| SCHEMBL2512041 | 0.88 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1ALOX5APFEN1F10 | |
| SCHEMBL17387504 | 0.87 | HSP90AA1 (0.66) | HSP90AA1HSP90AB1ALOX5APFEN1HPGD | |
| SCHEMBL2338324 | 0.86 | HSP90AA1 (0.64) | HSP90AA1HSP90AB1ALOX5APFEN1F10 | |
| SCHEMBL17387534 | 0.86 | HSP90AA1 (0.61) | HSP90AA1HSP90AB1ALOX5APFEN1F10 | |
| SCHEMBL12199704 | 0.85 | HSP90AA1 (0.57) | HSP90AA1HSP90AB1ALOX5APFEN1F10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2356110-B1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-06 | — | — | EP | claimed |
| EP-2356110-B1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-06 | — | — | EP | disclosed |
| EP-2356110-B1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2016-01-06 | — | — | EP | disclosed |
| US-8546565-B2 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546565-B2 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-8546565-B2 | Quinazolinamide derivatives | MERCK PATENT GESELLSCHAFT (DE) | 2013-10-01 | — | — | US | disclosed |
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) | 2011-10-06 | — | — | US | disclosed |
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTING (DE) | 2011-10-06 | — | — | US | disclosed |
| EP-2356110-A1 | QUINAZOLINAMIDE DERIVATIVES | Merck Patent GmbH (DE) | 2011-08-17 | — | — | EP | disclosed |
| WO-2010066324-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-17 | — | — | WO | disclosed |
| WO-2010066324-A1 | QUINAZOLINAMIDE DERIVATIVES | MERCK PATENT GMBH (DE) | 2010-06-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245225-A1 | QUINAZOLINAMIDE DERIVATIVES | HSP90AB1, HSP90AA1, HSP90B1 | HSP90AA1 2/4885HSP90AB1 1/4885ALOX5AP 4608/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.